The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the effect of escalating doses of cystine binding thiol drugs on the cystine capacity of the urine. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger dosages.
Cystinuria is a rare genetic disease that can lead to significant morbidity in affected patients due to the recurrent nature of the disease. This study will follow the levels of urine cystine capacity in order to help guide treatment and to use lower than usually prescribed Tiopronin doses to decrease the potential side effects while maintaining therapeutic benefit. This will increase adherence with the medications by decreasing the burden of the large number of pills that need to be taken daily.

开始日期2018-11-01

申办/合作机构

NYU Langone Health

NCT01095731 / Completed临床2期IIT

Phase II Study of the Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population.
Funding Source - FDA Office of Orphan Products Development

开始日期2010-04-01

申办/合作机构

University of Washington

[+2]

100 项与硫普罗宁相关的临床结果

登录后查看更多信息

100 项与硫普罗宁相关的转化医学

登录后查看更多信息

100 项与硫普罗宁相关的专利（医药）

登录后查看更多信息

746

项与硫普罗宁相关的文献（医药）

2024-03-01·Therapie

Drug-induced glomerular diseases

Review

作者: Laubacher, Hélène ; Garnier, Anne-Sophie ; Briet, Marie

Drug-induced kidney diseases represent a wide range of diseases that are responsible for a significant proportion of all acute kidney injuries and chronic kidney diseases. In the present review, we focused on drug-induced glomerular diseases, more precisely podocytopathies - minimal change diseases (MCD), focal segmental glomerulosclerosis (FSGS) - and membranous nephropathies (MN), from a physiological and a pharmacological point of view. The glomerular filtration barrier is composed of podocytes that form foot processes tightly connected and directly in contact with the basal membrane and surrounding capillaries. The common clinical feature of these diseases is represented by the loss of the ability of the filtration barrier to retain large proteins, leading to massive proteinuria and nephrotic syndrome. Drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), D-penicillamine, tiopronin, trace elements, bisphosphonate, and interferons have been historically associated with the occurrence of MCD, FSGS, and MN. In the last ten years, the development of new anti-cancer agents, including tyrosine kinase inhibitors and immune checkpoint inhibitors, and research into their renal adverse effects highlighted these issues and have improved our comprehension of these diseases.

2023-09-20·ACS applied materials & interfaces

Chemical Modification of Tiopronin for Dual Management of Cystinuria and Associated Bacterial Infections.

Article

作者: Garren, Mark Richard Stephen ; Handa, Hitesh ; Kumar, Anil ; Estes Bright, Lori M ; Manuel, James ; Shome, Arpita

Cystinuria is an inherited autosomal recessive disease of the kidneys of recurring nature that contributes to frequent urinary tract infections due to bacterial growth and biofilm formation surrounding the stone microenvironment. In the past, commonly used strategies for managing cystinuria involved the use of (a) cystine crystal growth inhibitors such as l-cystine dimethyl ester and lipoic acid, and (b) thiol-based small molecules such as N-(2-mercaptopropionyl) glycine, commonly known as tiopronin, that reduce the formation of cystine crystals by reacting with excess cystine and generating more soluble disulfide compounds. However, there is a dearth of simplistic chemical approaches that have focused on the dual treatment of cystinuria and the associated microbial infections. This work strategically exploited a single chemical approach to develop a nitric oxide (NO)-releasing therapeutic compound, S-nitroso-2-mercaptopropionyl glycine (tiopronin-NO), for the dual management of cystine stone formation and the related bacterial infections. The results successfully demonstrated that (a) the antibacterial activity of NO rendered tiopronin-NO effective against the stone microenvironment inhabitants, Escherichia coli and Pseudomonas aeruginosa, and (b) tiopronin-NO retained the ability to undergo disulfide exchange with cystine while being reported to be safe against canine kidney and mouse fibroblast cells. Thus, the synthesis of such a facile molecule aimed at the dual management of cystinuria and related infections is unprecedented in the literature.

2023-08-01·Current urology reports

Outcomes of Paediatric Cystine Stone Management: Results of a Systematic Review.

Review

作者: Geraghty, Robert ; Somani, Bhaskar ; Pietropaolo, Amelia ; Griffin, Stephen ; Cook, Paul ; Ripa, Francesco

PURPOSE OF REVIEW:

We wanted to analyse the outcomes of surgical (SWL, URS, PCNL) and medical management of cystine stones in the paediatric population in terms of stone-free status and complication rates, based on all the available literature evidence.

RECENT FINDINGS:

A systematic review of literature was performed for all studies with paediatric cystine stone management. Twelve studies met the eligibility criteria, of which 4 analysed outcomes of SWL, 2 of URS and 3 of PCNL and 3 focused on the effect of either alkalising agents (potassium citrate, citric acid) or cysteine-binding thiol (CBT) agents (tiopronin, penicillamine). The reported SFR in studies ranged from 50 to 83%, 59 to 100% and 63 to 80.6%, with a complication rate of 2.8-51%, 14-27% and 12.9-15.4% with SWL, URS and PCNL, respectively. Paediatric cystine stones treatment should aim at complete stone clearance, preservation of renal function and prevention of further recurrences. SWL achieves inferior results in case of cystine stones. URS and PCNL are safe and effective procedures in the paediatric population, with a low rate of major complications. Adherence to medical prevention therapies may prolong recurrence-free periods.

项与硫普罗宁相关的新闻（医药）

2024-06-06

·BioSpace

Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

Represents an immediate, compelling cash premium of 98% over Vanda’s closing share price prior to the initial Future Pak proposal announced on April 17, 2024 Vanda shares have not traded at $8.00 per share since January 2023 and have traded as low as $3.30 per share in the past twelve months Cycle has an extensive U.S. operational footprint and distribution footprint, a strong strategic fit for Vanda’s commercialized therapies and clinical development pipeline Cycle and its advisors are standing by to work immediately with Vanda’s Board and management team to quickly negotiate and finalize a definitive agreement BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)-- Cycle Pharmaceuticals Ltd (“Cycle” or the “Company”), a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million. Cycle’s proposal represents: - Immediate and certain cash value for all Vanda shareholders; - A 98% premium above Vanda’s closing share price on April 16, 2024, the day prior to the public disclosure of the initial offer by Future Pak LLC of $4.05 per share; - A 63% premium above Vanda’s closing share price on May 23, 2024, the day before Cycle submitted its proposal to the Vanda Board; - An all-cash upfront offer exceeding the cash portion of Future Pak’s revised proposal for Vanda on May 7, 2024; and - A 58% premium above Vanda’s closing share price on June 5, 2024. Cycle has substantial cash on hand, and both of Cycle’s financial advisors are highly confident that, following limited due diligence, committed financing will be put in place for the transaction. Cycle will obtain fully underwritten, binding commitment letters for any debt financing prior to signing a definitive merger agreement, which will not contain any financing contingency. Cycle issued the following statement regarding its proposal: “Our proposal for Vanda delivers immediate, compelling and certain cash value for Vanda shareholders with a highly attractive premium. Cycle’s proposal represents a better outcome for shareholders, who would receive all-cash upfront value exceeding that of Future Pak’s cash portion of its latest offer announced May 7, 2024. It would also benefit patients, as Cycle has a proven commercial strategy in the U.S., a strong distribution footprint and an established track record of delivering medicines and individualized support to patients suffering from conditions with high unmet medical need. While we would have preferred to reach an agreement privately, Cycle is publicly disclosing our proposal for the benefit of Vanda shareholders and to encourage Vanda shareholders to express their views on this proposal to the independent directors of the Vanda Board of Directors. Given our familiarity with Vanda, its brands and our extensive knowledge of the industry, we believe we can efficiently and quickly complete our diligence. Once we receive access to the required information, we believe that we can complete our due diligence within 2-3 weeks and reach a definitive agreement shortly thereafter. We stand ready to work immediately with Vanda’s Board and management team to reach an agreement that would provide a compelling premium and certain cash value today for all Vanda shareholders.” About Cycle Pharmaceuticals Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community, and the healthcare professionals and communities that support them. Cycle focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, Cycle focuses on multiple sclerosis. During May 2024, Cycle launched its 6th drug product in the U.S. market. Cycle’s U.S. commercial drug products are: NITYR® (nitisinone) Tablets (since 2017) SAJAZIR™ (icatibant) Injection (since 2021) JAVYGTOR™ (sapropterin dihydrochloride) Tablets and Powder (since 2022) TASCENSO ODT® (fingolimod) (since 2023) TIOPRONIN delayed-release tablets (since 2024) ORMALVI™ (dichlorphenamide) Tablets (since 2024) Cycle achieved $109m net sales and $40m operating profit in 2023 (according to FRS102 accounting principles). Extracts of the Company’s unaudited financial results for the year ending December 31, 2023 are available here. Cycle is headquartered in Cambridge, U.K. and has offices in Boston, Massachusetts. For more information, please visit and follow us on X, LinkedIn and Facebook. Additional Information The terms of this announcement are non-binding and intended solely to provide the basis on which Cycle is presently willing to negotiate definitive transaction documentation in respect of the proposal, and are not intended to, and should not be deemed or construed to, create or constitute any sort of binding offer, commitment, right or obligation on the part of Cycle, Vanda, Vanda’s shareholders, or their respective affiliates. Any such offer, commitment, right or obligation will come into existence only by the execution and delivery of binding definitive transaction documentation by the parties setting forth the terms and conditions of such offer, right, commitment or obligation, and will be subject in each case to the satisfaction or waiver of all applicable conditions. The failure for any reason to execute and deliver the definitive transaction documentation or consummate the proposal will impose no liability on any party hereto or their respective affiliates.

财报并购

2024-05-13

·BioSpace

New tiopronin delayed-release tablets launch with patient support for the treatment of cystinuria in the US

BOSTON--(BUSINESS WIRE)-- Cycle Pharmaceuticals Limited (Cycle) is pleased to announce the launch of tiopronin delayed-release tablets as a treatment option for patients with cystinuria.1 Tiopronin delayed-release tablets are available in 100 mg and 300 mg doses, and are approved by the US Food and Drug Administration (FDA).1 Generic tiopronin delayed-release tablets must be taken without food.1 Cystinuria is the most common inheritable cause of kidney stone disease. Incidence of the condition is estimated to be 1 in 7,000 worldwide.2 The launch of tiopronin delayed-release tablets is a partnership between Cycle and Torrent Pharma Inc. (Torrent) utilizing Anovo Specialty Pharmacy (Anovo) in which all three companies are committed to providing patients with rare diseases the medication and patient support they need. Tiopronin delayed-release tablets are a treatment option for patients with cystinuria who want to benefit from the support services provided by Cycle Vita™, a dedicated support platform which provides individualized product support* for patients, and ongoing dispensing and support services provided by Anovo, the exclusive specialty pharmacy for this product. “Cystinuria is a chronic lifelong condition in which stones commonly reoccur.3 In addition, close control of a patient’s diet, specifically a reduction in salt and methionine intake, can have an impact on the likelihood of stones forming.3 We are fully aware of the unique personal challenges these patients face in effectively managing their cystinuria. That’s why we’re providing individualized support including a Bridge Program* and Co-pay Assistance Program*. In addition, a Patient Nutrition Program* will be available to reinforce the clinic’s nutrition plan,” says Chikai Lai, SVP & Chief Commercial Officer, Cycle. Tiopronin delayed-release tablets are Cycle’s fifth commercial product to be launched in the US, building on the launch of: NITYR® (nitisinone) Tablets in 2017 SAJAZIR™ (icatibant) Injection in 2021 JAVYGTOR™ (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution in 2022; and TASCENSO ODT® (fingolimod) in 2023 Tiopronin delayed-release tablets are indicated in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Tiopronin delayed-release tablets must be taken without food.1 To find out more about Cycle Vita, please visit or call +1 (888) 360-8482 and find the Full Prescribing Information available at . Important Safety Information Important Safety Information is below. Full Prescribing Information is available at . INDICATIONS Tiopronin delayed-release tablets are a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for prevention of cystine stone formation in adult and pediatric patients 9 years of age and older with severe homozygous cystinuria who are not responsive to these measures alone. WARNINGS AND PRECAUTIONS Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported. MOST COMMON ADVERSE REACTIONS Most common adverse reactions (≥10%) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis. DRUG INTERACTIONS Alcohol: Tiopronin is released faster from tiopronin delayed-release tablets in the presence of alcohol and the risk for adverse events associated with tiopronin delayed-release tablets when taken with alcohol is unknown. Avoid alcohol consumption 2 hours before and 3 hours after taking tiopronin delayed-release tablets. USE IN SPECIFIC POPULATIONS: Pregnancy: Available published case report data with tiopronin have not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse pregnancy outcomes. Tell your healthcare provider immediately if you become pregnant or planning to become pregnant. Lactation: There are no data on the presence of tiopronin in either human or animal milk or on the effects of the breastfed child. A published study suggests that tiopronin may suppress milk production. Because of the potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not recommended during treatment with tiopronin delayed-release tablets. Tell your healthcare provider immediately if you plan on breast feeding. Pediatric Use: Tiopronin delayed-release tablets are indicated in pediatric patients 9 years of age and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation who are not responsive to these measures alone. Tiopronin delayed-release tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients unable to swallow tablets. Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. For more detailed information, please refer to the full Prescribing Information at . If you get any side effects, talk to your healthcare provider. This includes possible side effects not listed in this material. You may also report side effects directly by calling Torrent Pharma Inc. at: 1-800-912-9561 or FDA at: 1-800-FDA-1088 or . This material is for education purposes only. It is not intended to be, and should not be used as, a substitute for medical advice. US-TIO-2400004 (February 2024) References Tiopronin Delayed-Release Tablets. Prescribing Information. Torrent Pharma Inc. Leslie, S.W., Sajjad, H. and Nazzal, L. (2023). Cystinuria. [online] Nih.gov. Available at: [Accessed Feb 9 2024]. Cystinuria UK - Diet - what should I eat (2023). Cystinuria UK - Diet - what should I eat? [online] Cystinuriauk.co.uk. Available at: [Accessed Feb 9 2024]. * Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482. The US Prescribing Information provides the indications for which the product is approved in the US. Please consult the US Prescribing Information and product labeling for information about the specific uses for which the product is indicated in the US. –ENDS– Cycle Vita™, SAJAZIR™ and JAVYGTOR™ are trademarks of Cycle Pharmaceuticals Limited in the United States. NITYR® is a registered trademark of Cycle Pharmaceuticals Limited in the United States. TASCENSO ODT® is a registered trademark of Handa Neuroscience, LLC. ©2024 Cycle Pharmaceuticals Limited. All rights reserved. About Cycle Pharmaceuticals Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community. Cycle focuses on rare metabolic, immunological, and neurological genetic conditions. Within neurological conditions, we focus on multiple sclerosis. Cycle is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit and follow us on X, LinkedIn and Facebook. About Torrent Pharma Inc. Torrent Pharma is one of the leading Pharma companies in India. Torrent is the pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). Torrent also has significant presence in diabetology, pain management, gynecology, oncology and anti-infective segments. Torrent Pharma is present in more than 40 countries. It is ranked first amongst Indian Companies for having largest market share in Brazil and Germany. About Anovo Anovo was founded in 2012 as an exclusive provider of comprehensive end-to-end services for manufacturers of rare disease drugs and patients who need the drugs, including specialty wholesale/3PL distribution services, specialty pharmacy services, and patient support hub programs. Anovo benefits all parties involved by navigating all the complexities of managing rare disease medications and providing the related support needed by patients, caregivers and prescribers. View source version on businesswire.com: Contacts Marketing@cyclepharma.com Cycle Pharmaceuticals Tel: +44 1223 354 118 Source: Cycle Pharmaceuticals Limited View this news release online at:

上市批准

2024-05-10

·医药地理

“爱眼日”将近，重点眼病药品数据观察

2024年6月6日是第29个全国“爱眼日”。为进一步贯彻落实习近平总书记关于眼健康工作重要指示批示精神，切实推动《“十四五”全国眼健康规划（2021—2025年）》落到实处，充分调动社会各界积极性，提高人民群众爱眼护眼意识，国家卫健委于5月7日发布关于开展2024年全国“爱眼日”宣传教育周活动的通知。今年全国“爱眼日”宣传教育周活动主题为“关注普遍的眼健康”，活动将重点聚焦近视等屈光不正、白内障、眼底病、青光眼、角膜盲等重点眼病，着重关注儿童青少年、老年人两个重点人群，大力宣传全年龄段全生命周期眼健康的重要意义。本文我们将从重点眼病相关的药品数据出发，了解相关疾病和药品，关注眼健康。屈光不正当眼调节静止时，外界的平行光线经过眼睛的屈光系统，但不能在视网膜黄斑中心凹聚焦，因此无法产生清晰的成像，此种情况称为屈光不正（refractive error）或非正视（ametropia）。屈光不正包括近视、远视和散光。随着科技水平的发展及电子产品的普及，屈光不正在人群中，尤其是青少年中的发病率逐渐升高，且发病年龄逐渐减小。其中近视是最常见的屈光不正，影响近30%的人口。在PDB药物综合数据库中检索适应症为“屈光不正”的药品，常用的药品有康柏西普眼用注射液、复方尿维氨滴眼液、四味珍层冰硼滴眼液等。图：治疗屈光不正的药品销售额来源：PDB药物综合数据库，全渠道放大康柏西普（Conbercept）是一种抗血管内皮生长因子的融合蛋白，可以抑制病理性血管生成。康柏西普也是中国首个获得世界卫生组织国际通用名的、拥有全自主知识产权的生物I类新药，专利持有人为成都康弘生物科技有限公司（Chengdu Kanghong Biotechnologies Co. Ltd）。2021年，康柏西普全国销售额为15.94亿元，2022年销售额为13.66亿元，2023年Q1-Q3销售额为13.74亿元，推算全年销售额为18.28亿元，预计2024年销售额有望超过19亿元。图：康柏西普中国销售额来源：Pharma ONE智能药物大数据分析平台白内障白内障晶状体是人眼球中重要的光学部件，正常情况下是透明的。由于各种原因导致晶状体蛋白质变性而发生混浊，致使患者出现不同程度的视力下降，称为白内障（cataract）。全球盲人中因白内障致盲者约占46%，是全球第一位致盲性眼病。各型白内障中，最常见的是老年性白内障，多出现于50岁以上的中老年人。我国西藏地区白内障发病率最高，与紫外线的辐射有关。此外，随着生活水平的提高，糖尿病等代谢疾病的发病率逐年增加，白内障有逐渐低龄化的趋势。目前适应症为白内障的常用药物有注射用硫普罗宁、苄达赖氨酸滴眼液、氟米龙滴眼液、复明片等。图：治疗白内障的药品销售额来源：PDB药物综合数据库，全渠道放大硫普罗宁为一种新型含游离巯基的甘氨酸衍生物。能赋活代谢酶，并能和阻碍HS-酶活性的有毒物质相螯合，因而有解毒作用，可以升高白细胞并加速肝细胞的恢复，降低骨髓染色体畸变率和皮肤溃疡的发生。因此，硫普罗宁的临床应用较为广泛，在国内共涉及包括早期老年性白内障、酒精性脂肪肝、药物性肝损伤在内的13种疾病，在全球则扩大至19种疾病。图：硫普罗宁的在研适应症来源：Pharma ONE智能药物大数据分析平台氟米龙滴眼液属于皮质类固醇类抗炎药，可抑制由机械、化学或免疫原性等刺激因子导致的炎症。临床常用于治疗对皮质类固醇敏感的外眼部及眼前部组织的炎症，如眼睑炎、结膜炎、角膜炎及手术后炎症等。全球共有39家公司参与氟米龙药物开发，14家公司获批；国内则有19家公司参与氟米龙药物开发，6家公司获批。图：氟米龙滴眼液参与研发公司现状来源：Pharma ONE智能药物大数据分析平台青光眼青光眼是一组进行性视神经损害、最终损伤视力的疾病的统称，主要与病理性的眼压升高有关。青光眼是全球导致失明的第二大病因，仅次于白内障，却是第一位不可逆致盲眼病。预计到2020年，我国全人群青光眼患者将达到2182万（占全球27.4%），40岁以上人群患病率将达到3.05%，居世界首位。青光眼的治疗原则是降低患者的眼内压，主要治疗方式有滴眼药水、口服降眼压药物、激光治疗、手术等。常用药品有：布林佐胺滴眼液、拉坦前列腺素滴眼液、酒石酸溴莫尼定滴眼液等。图：治疗青光眼的药品销售额来源：PDB药物综合数据库，全渠道放大布林佐胺滴眼液是眼科常用的降低眼压的药物，属于一种碳酸酐酶抑制剂，通过抑制眼部睫状突的碳酸酐酶以减少眼球内部房水的分泌，或阻止碳酸氢盐离子的生成而减少钠/水转运，从而使眼压降低。目前，我国仅有1种布林佐胺滴眼液批准上市，生产企业为Novartis Europharm Ltd。图：布林佐胺滴眼液国内获批情况来源：CPM新药研发监测数据库拉坦前列素滴眼液为选择性前列腺素FP受体激动剂，通过增加房水流出而降低眼压，主要的临床适应证是开角型青光眼和高眼压症。2022年，拉坦前列素在中国销售额为1.32亿元人民币，包括拉坦前列素（1.25亿元人民币）和拉坦前列素+噻吗洛尔的复方制剂，全球销量10.56亿美元，单品销售额约7亿美元。图：2022年拉坦前列素销售额来源：Pharma ONE智能药物大数据分析平台总结图：2015-2023 眼科疾病治疗药品销售额来源：PDB药物综合数据库，全渠道放大上图为2015年至今的眼科疾病药品销售金额，从中可以看出眼科疾病用药总体呈增长趋势，其原因主要有两个：白内障、老年性黄斑病变等疾病与人口老龄化密切相关，过度的电子产品使用时长也使得年轻人眼病发生率提高。随着第29个全国“爱眼日”临近，也希望各位朋友多多了解眼健康常识，培养正确就医理念，提高儿童、老年人等重点人群早筛早诊早治意识，当好自己健康第一责任人，守护“眼健康”。END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

引进/卖出医药出海

100 项与硫普罗宁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01430	硫普罗宁	G04BX16	DB06823

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脂肪肝	中国	河南中康药业有限公司	1998-01-01
酒精性肝疾病	中国	河南中康药业有限公司	1998-01-01
慢性肝炎	中国	江苏亚邦爱普森药业有限公司	1995-01-01
慢性肝炎	中国	常州亚邦制药有限公司	1995-01-01
胱氨酸尿症	美国	Mission Pharmacal Co.	1988-08-11
尿石症	美国	Mission Pharmacal Co.	1988-08-11
白内障	日本	Mylan Pharmaceuticals, Inc.	1979-08-27
汞中毒	日本	Mylan Pharmaceuticals, Inc.	1979-08-27
慢性肝病	日本	Mylan Pharmaceuticals, Inc.	1970-03-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03663855 (CTgov)	临床2期	胱氨酸尿症	10	Tiopronin	遞蓋襯鏇夢齋齋夢簾膚(製觸蓋糧網選齋餘構願) = 膚壓簾鹹憲選構衊鹹顧積網淵醖膚餘醖鑰憲鏇 (餘壓鹹願遞範襯顧艱選, 淵簾製蓋憲艱廠鬱窪構 ~ 醖鏇鹹範餘鏇衊遞鹹膚) 更多	-	2021-12-17
ASN2020	N/A	微小病变性肾病	-	Tiopronin 300 mg bid	構繭積繭憲餘簾築淵鑰(襯積製選襯鹹構鑰夢壓) = 鏇蓋廠範願襯積艱構膚窪糧簾製膚積艱衊膚積 (鏇廠膚餘鑰構範膚窪醖 )	积极	2020-10-19
NCT01095731 (Pubmed \| J Neurosurg)	临床2期	颅内动脉瘤1	60	Tiopronin	顧願鬱簾廠襯蓋蓋窪構(糧鏇鏇製襯繭淵艱廠淵) = 範窪醖鹽衊壓鬱觸構窪網鏇積繭膚壓廠願窪鏇 (窪範鹹艱願夢積觸憲膚 )	-	2019-07-12
NCT01095731 (Pubmed \| J Neurosurg)	临床2期	颅内动脉瘤1	60	Placebo	顧願鬱簾廠襯蓋蓋窪構(糧鏇鏇製襯繭淵艱廠淵) = 蓋壓積壓鏇憲糧簾窪網網鏇積繭膚壓廠願窪鏇 (窪範鹹艱願夢積觸憲膚 )	-	2019-07-12
AUA2017	N/A	胱氨酸贮积症	42	THIOLA (Bilateral cystine stone formers)	鏇憲糧網觸鹹築憲廠糧(觸衊網鬱夢範鬱醖顧觸) = 積醖鬱簾範簾簾衊範繭獵窪簾鹽網齋淵積觸鹽 (觸蓋築襯製鏇醖窪築構 )	-	2017-04-01
AUA2017	N/A	胱氨酸贮积症	42	THIOLA (Unilateral cystine stone formers)	鏇憲糧網觸鹹築憲廠糧(觸衊網鬱夢範鬱醖顧觸) = 願衊鹹積製範齋觸築鑰獵窪簾鹽網齋淵積觸鹽 (觸蓋築襯製鏇醖窪築構 )	-	2017-04-01